3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 3
1
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
4
Other hematologic neoplasm
2
Sarcoma
1
Other solid neoplasm
1
Myeloid
1
Genitourinary
1
Gastrointestinal
1
CNS
1
Conditions
Wilms Tumor
1
Sarcoma, Ewing
1
Sarcoma, Clear Cell
1
Sarcoma
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Retinoblastoma
1
Osteosarcoma
1
Neuroblastoma
1
Neoplasms, Germ Cell and Embryonal
1
Hepatoblastoma
1
Carcinoma, Renal Cell
1
Interventions
Gemcitabine
218
Fluorouracil
142
Oxaliplatin
132
Capecitabine
122
pembrolizumab
113
Irinotecan
110
Leucovorin
104
Bevacizumab
98
Nivolumab
80
Cisplatin
80
130-nm albumin-bound paclitaxel
80
Cetuximab
79
Radiotherapy
78
Albumin-Bound Paclitaxel
59
Sorafenib
56
Paclitaxel
53
Cyclophosphamide
50
Carboplatin
47
Magnetic Resonance Spectroscopy
44
Specimen Handling
39
Docetaxel
37
Taxes
36
fludarabine
34
Radiation
34
durvalumab
33
Ipilimumab
33
Erlotinib Hydrochloride
33
Biopsy
33
Radiosurgery
27
Folfox protocol
27
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
pegylated granulocyte colony-stimulating factor
×
Gastrointestinal
×
Clear all
NCT02390843
2020-04-03
AflacST1402
Emory University
Phase 1
Completed
13 enrolled